Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
What a wobby AI trade could mean for Anthropic's IPO
Despite recent AI jitters, strategists expect strong demand for Anthropic’s potentially historic IPO.
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
What inflation-resistant businesses have in common.
stocks
Our view after REA’s share price rally
A bullish market reaction but valuation concerns remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.40 | 18.70 | 0.20% |
| CAC 40 | 8,205.75 | 66.75 | 0.82% |
| DAX 40 | 26,099.34 | 278.98 | 1.08% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,751.39 | 77.45 | 0.73% |
| HKSE | 24,448.95 | 32.91 | -0.13% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 58,775.50 | 1,340.73 | 2.33% |
| NZX 50 Index | 13,973.62 | 24.88 | -0.18% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 9,029.70 | 8.90 | 0.10% |
| SSE Composite Index | 3,660.79 | 11.61 | 0.32% |